Targeted Therapy for Preeclampsia
Advanced Prenatal Therapeutics (APT) is developing a novel
therapeutic device for treating preeclampsia by specifically removing
harmful substances from the mother’s blood.
There are currently no other therapies available to specifically treat preeclampsia. In
managing preeclampsia, the main objective is the health and survival of the mother.
Premature induction of delivery, regardless of gestational age, remains the only
treatment option. Our targeted therapy for preeclampsia is a simple procedure in which
disease-causing factors in the mother's blood are specifically removed with APT's
Targeted Apheresis Cartridge for Preeclampsia (TAC-PE), while the blood components
that are natural and vital are preserved.
APT's mission is to develop an effective treatment that will safely prolong pregnancy,
allowing babies more time to develop in the womb. Treatment with the TAC-PE will
potentially extend the duration of pregnancy, thereby reducing the risk of lifelong
disabilities in babies resulting from prematurity and IUGR.
Preeclampsia affects 5-8% of
300,000 women in the United
States every year.
In the US, approximately 10,500
babies die due to preeclampsia
each year, and an estimated
Preeclampsia is a leading cause
of maternal illness and death. It
accounts for 20% of maternal
deaths, and doubles the future
risk of cardiovascular and
Preeclampsia is a major cause of
prematurity and intrauterine
growth restriction (IUGR), which
lead to lifelong challenges such
as cardiovascular disease,
learning disorders, cerebral
palsy, epilepsy, blindness, and
The only way to “cure”
preeclampsia is to deliver the
baby and remove the placenta,
regardless of gestational age.
Copyright © 2013 Advanced Prenatal Therapeutics, Inc
Images courtesy of Tom Clare (left) and David Castillo
Dominici (center) via FreeDigitalPhotos.net